دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
Claudio Luchini, Robert C Grant, Aldo Scarpa, Steven Gallinger
doi : 10.1136/gutjnl-2020-323805
Gut 2021;70:1809-1811.
Transcolonic endoscopic appendectomy: a novel natural orifice transluminal endoscopic surgery (NOTES) technique for the sessile serrated lesions involving the appendiceal orifice
Tao Chen, Aiping Xu, Jingjing Lian, Yuan Chu, Haibin Zhang, Meidong Xu
doi : 10.1136/gutjnl-2020-323018
Gut 2021;70:1812-1814.
Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community
Francis Megraud, Robin Bruyndonckx, Samuel Coenen, Linda Wittkop, Te-Din Huang, Martin Hoebeke, Lucie Bénéjat, Philippe Lehours, Herman Goossens, Youri Glupczynski
doi : 10.1136/gutjnl-2021-324032
Gut 2021;70:1815-1822.
Our aim was to prospectively assess the antibiotic resistance rates in Helicobacter pylori strains in Europe in 2018 and to study the link between antibiotic consumption in the community and H. pylori resistance levels in the different countries.
Original research: Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination
Raghav Sundar, Drolaiz HW Liu, Gordon GA Hutchins, Hayley L Slaney, Arnaldo NS Silva, Jan Oosting, Jeremy D Hayden, Lindsay C Hewitt, Cedric CY Ng, Amrita Mangalvedhekar, Sarah B Ng, Iain BH Tan, Patrick Tan, Heike I Grabsch
doi : 10.1136/gutjnl-2020-320805
Gut 2021;70:1823-1832.
Endoscopic mucosal biopsies of primary gastric cancers (GCs) are used to guide diagnosis, biomarker testing and treatment. Spatial intratumoural heterogeneity (ITH) may influence biopsy-derived information. We aimed to study ITH of primary GCs and matched lymph node metastasis (LNmet).
Original research: Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair
Junichi Matsuo, Daisuke Douchi, Khine Myint, Naing Naing Mon, Akihiro Yamamura, Kazuyoshi Kohu, Dede Liana Heng, Sabirah Chen, Nur Astiana Mawan, Napat Nuttonmanit, Ying Li, Supriya Srivastava, Shamaine Wei Ting Ho, Nicole Yee Shin Lee, Hong Kai Lee, Makoto Adachi, Atsushi Tamura, Jinmiao Chen, Henry Yang, Ming Teh, Jimmy Bok-Yan So, Wei Peng Yong, Patrick Tan, Khay Guan Yeoh, Linda Shyue Huey Chuang, Sachiko Tsukita, Yoshiaki Ito
doi : 10.1136/gutjnl-2020-322779
Gut 2021;70:1833-1846.
Tissue stem cells are central regulators of organ homoeostasis. We looked for a protein that is exclusively expressed and functionally involved in stem cell activity in rapidly proliferating isthmus stem cells in the stomach corpus.
Original research: Serum glucose excretion after Roux-en-Y gastric bypass: a potential target for diabetes treatment
In Gyu Kwon, Chan Woo Kang, Jong-Pil Park, Ju Hun Oh, Eun Kyung Wang, Tae Young Kim, Jin Sol Sung, Namhee Park, Yang Jong Lee, Hak-Joon Sung, Eun Jig Lee, Woo Jin Hyung, Su-Jin Shin, Sung Hoon Noh, Mijin Yun, Won Jun Kang, Arthur Cho, Cheol Ryong Ku
doi : 10.1136/gutjnl-2020-321402
Gut 2021;70:1847-1856.
The mechanisms underlying type 2 diabetes resolution after Roux-en-Y gastric bypass (RYGB) are unclear. We suspected that glucose excretion may occur in the small bowel based on observations in humans. The aim of this study was to evaluate the mechanisms underlying serum glucose excretion in the small intestine and its contribution to glucose homeostasis after bariatric surgery.
NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NF?B in colitis
Semih Can Ak?nc?lar, Lele Wu, Qin Feng NG, Joelle Yi Heng Chua, Bilal Unal, Taichi Noda, Wei Hong Jeff Chor, Masahito Ikawa, Vinay Tergaonkar
doi : 10.1136/gutjnl-2020-322980
Gut 2021;70:1857-1871.
NF?B is the key modulator in inflammatory disorders. However, the key regulators that activate, fine-tune or shut off NF?B activity in inflammatory conditions are poorly understood. In this study, we aim to investigate the roles that NF?B-specific long non-coding RNAs (lncRNAs) play in regulating inflammatory networks.
Original research: Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
Xiaolong He, Jie Gao, Liang Peng, Tongtong Hu, Yu Wan, Meijuan Zhou, Peilin Zhen, Hong Cao
doi : 10.1136/gutjnl-2020-322468
Gut 2021;70:1872-1883.
O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation. Gut microbiota encode various enzymes involved in O-GlcNAcylation. However, the characteristics, abundance and function of these enzymes are unknown.
Original research: Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A Kennedy, Simeng Lin, James R Goodhand, Neil Chanchlani, Benjamin Hamilton, Claire Bewshea, Rachel Nice, Desmond Chee, JR Fraser Cummings, Aileen Fraser, Peter M Irving, Nikolaos Kamperidis, Klaartje B Kok, Christopher Andrew Lamb, Jonathan Macdonald, Shameer Mehta, Richard CG Pollok, Tim Raine, Philip J Smith, Ajay Mark Verma, Simon Jochum, Timothy J McDonald, Shaji Sebastian, Charlie W Lees, Nick Powell, Tariq Ahmad
doi : 10.1136/gutjnl-2021-324789
Gut 2021;70:1884-1893.
Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine.
Original research: Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Robert C Grant, Robert Denroche, Gun Ho Jang, Klaudia M Nowak, Amy Zhang, Ayelet Borgida, Spring Holter, James T Topham, Julie Wilson, Anna Dodd, Raymond Jang, Rebecca Prince, Joanna M Karasinska, David F Schaeffer, Yifan Wang, George Zogopoulos, Scott Berry, Diane Simeone, Daniel J Renouf, Faiyaz Notta, Grainne O'Kane, Jennifer Knox, Sandra Fischer, Steven Gallinger
doi : 10.1136/gutjnl-2020-320730
Gut 2021;70:1894-1903.
To describe the clinical, pathological and genomic characteristics of pancreatic cancer with DNA mismatch repair deficiency (MMRD) and proficiency (MMRP).
Original research: Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours
Kate Young, Rita T Lawlor, Chanthirika Ragulan, Yatish Patil, Andrea Mafficini, Samantha Bersani, Davide Antonello, David Mansfield, Sara Cingarlini, Luca Landoni, Antonio Pea, Claudio Luchini, Liliana Piredda, Nagarajan Kannan, Gift Nyamundanda, Daniel Morganstein, Ian Chau, Bertram Wiedenmann, Michele Milella, Alan Melcher, David Cunningham, Naureen Starling, Aldo Scarpa, Anguraj Sadanandam
doi : 10.1136/gutjnl-2020-321016
Gut 2021;70:1904-1913.
A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify potential therapeutic vulnerabilities in this disease.
COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
Luca Saverio Belli, Christophe Duvoux, Paolo Angelo Cortesi, Rita Facchetti, Speranta Iacob, Giovanni Perricone, Sylvie Radenne, Sara Conti, Damiano Patrono, Gabriela Berlakovich, Angus Hann, Luisa Pasulo, Lluis Castells, Francois Faitot, Olivier Detry, Federica Invernizzi, Giulia Magini, Paolo De Simone, Ilias Kounis, Maria Cristina Morelli, Fernando Díaz Fontenla, Bo-Göran Ericzon, Carmelo Loinaz, Chris Johnston, Liliana Gheorghe, Mickael Lesurtel, Renato Romagnoli, Dagmar Kollmann, M Thamara PR Perera, Stefano Fagiuoli, Darius Mirza, Audrey Coilly, Christian Toso, Krzysztof Zieniewicz, Laure Elkrief, Vincent Karam, Rene Adam, Caroline den Hoed, Marco Merli, Massimo Puoti, Luciano De Carlis, Gabriel C Oniscu, Salvatore Piano, Paolo Angeli, Constantino Fondevila, Wojciech G Polak
doi : 10.1136/gutjnl-2021-324879
Gut 2021;70:1914-1924.
Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course.
Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study
Sabine Weber, Johannes C Hellmuth, Clemens Scherer, Maximilian Muenchhoff, Julia Mayerle, Alexander L Gerbes
doi : 10.1136/gutjnl-2020-323800
Gut 2021;70:1925-1932.
Liver injury has frequently been reported in COVID-19 patients. The clinical relevance of liver injury related to SARS-CoV-2 infection remains unclear with a need for prospective studies on the impact of liver function test (LFT) abnormalities at baseline.
Original research: ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis
Liuyi Hao, Wei Zhong, Haibo Dong, Wei Guo, Xinguo Sun, Wenliang Zhang, Ruichao Yue, Tianjiao Li, Alexandra Griffiths, Ali Reza Ahmadi, Zhaoli Sun, Zhenyuan Song, Zhanxiang Zhou
doi : 10.1136/gutjnl-2020-321548
Gut 2021;70:1933-1945.
Mitochondrial dysfunction plays a dominant role in the pathogenesis of alcoholic liver disease (ALD); however, the underlying mechanisms remain to be fully understood. We previously found that hepatic activating transcription factor 4 (ATF4) activation was associated with mitochondrial dysfunction in ALD. This study aimed to investigate the function and mechanism of ATF4 in alcohol-induced hepatic mitochondrial dysfunction.
Original research: MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis
Jinho Jung, Rohan R Loomba, Kento Imajo, Egbert Madamba, Sanil Gandhi, Ricki Bettencourt, Seema Singh, Carolyn Hernandez, Mark A Valasek, Cynthia Behling, Lisa Richards, Katie Fowler, Claude B Sirlin, Atsushi Nakajima, Rohit Loomba
doi : 10.1136/gutjnl-2020-322976
Gut 2021;70:1946-1953.
Patients with non-alcoholic fatty liver disease (NAFLD) with ?stage 2 fibrosis are at increased risk for liver-related mortality and are candidates for pharmacological therapies for treatment of NAFLD. The aim of this prospective cohort study is to examine the diagnostic accuracy of MR elastography (MRE) combined with fibrosis-4 (FIB-4) in diagnosing ?stage 2 fibrosis (candidates for pharmacological therapies).
Original research: Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
Eun Hee Koh, Ji Eun Yoon, Myoung Seok Ko, Jaechan Leem, Ji-Young Yun, Chung Hwan Hong, Yun Kyung Cho, Seung Eun Lee, Jung Eun Jang, Ji Yeon Baek, Hyun Ju Yoo, Su Jung Kim, Chang Ohk Sung, Joon Seo Lim, Won-Il Jeong, Sung Hoon Back, In-Jeoung Baek, Sandra Torres, Estel Solsona-Vilarrasa, Laura Conde de la Rosa, Carmen Garcia-Ruiz, Ariel E Feldstein, Jose C Fernandez-Checa, Ki-Up Lee
doi : 10.1136/gutjnl-2020-322509
Gut 2021;70:1954-1964.
Lipotoxic hepatocyte injury is a primary event in non-alcoholic steatohepatitis (NASH), but the mechanisms of lipotoxicity are not fully defined. Sphingolipids and free cholesterol (FC) mediate hepatocyte injury, but their link in NASH has not been explored. We examined the role of free cholesterol and sphingomyelin synthases (SMSs) that generate sphingomyelin (SM) and diacylglycerol (DAG) in hepatocyte pyroptosis, a specific form of programmed cell death associated with inflammasome activation, and NASH.
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells
Ting Liu, Jizhou Tan, Minhao Wu, Wenzhe Fan, Jialiang Wei, Bowen Zhu, Jian Guo, Shutong Wang, Penghui Zhou, Hui Zhang, Liangrong Shi, Jiaping Li
doi : 10.1136/gutjnl-2020-322196
Gut 2021;70:1965-1977.
It remains controversial whether tumour mutational burden (TMB) or neoantigens are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the function of TMB or neoantigens in antitumour immunotherapy.
Calprotectin: from biomarker to biological function
Almina Jukic, Latifa Bakiri, Erwin F. Wagner, Herbert Tilg, Timon E. Adolph
doi : 10.1136/gutjnl-2021-324855
Gut 2021;70:1978-1988.
The incidence of inflammatory bowel diseases (IBD) emerged with Westernisation of dietary habits worldwide. Crohn’s disease and ulcerative colitis are chronic debilitating conditions that afflict individuals with substantial morbidity and challenge healthcare systems across the globe. Since identification and characterisation of calprotectin (CP) in the 1980s, faecal CP emerged as significantly validated, non-invasive biomarker that allows evaluation of gut inflammation. Faecal CP discriminates between inflammatory and non-inflammatory diseases of the gut and portraits the disease course of human IBD. Recent studies revealed insights into biological functions of the CP subunits S100A8 and S100A9 during orchestration of an inflammatory response at mucosal surfaces across organ systems. In this review, we summarise longitudinal evidence for the evolution of CP from biomarker to rheostat of mucosal inflammation and suggest an algorithm for the interpretation of faecal CP in daily clinical practice. We propose that mechanistic insights into the biological function of CP in the gut and beyond may facilitate interpretation of current assays and guide patient-tailored medical therapy in IBD, a concept warranting controlled clinical trials.
Recent advances in clinical practice: epidemiology of autoimmune liver diseases
Palak J Trivedi, Gideon M Hirschfield
doi : 10.1136/gutjnl-2020-322362
Gut 2021;70:1989-2003.
Autoimmune liver diseases are chronic inflammatory hepatobiliary disorders that when classically defined encompass three distinctive clinical presentations; primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Meaningful changes in disease epidemiology are reported, with increasing incidence and prevalence of AIH and PSC in Europe, and rising prevalence of PBC across Europe, North America and the Asia-Pacific region. However, there appears to be very significant global variation with contemporary incidence rates of disease per 100 000 ranging from 0.84 to 2.75 for PBC, 0.1 to 4.39 for PSC and 0.4 to 2.39 for AIH. Prevalence corresponds, and per 100 000 estimates for PBC range from 1.91 to 40.2, for PSC between 0.78 and 31.7 and for AIH from 4.8 to 42.9. Population-based studies and multicentre observational cohort series provide improved understanding of the clinical course that patients experience, highlighting variations in presenting phenotypes geographically and temporally. Collectively, while autoimmune liver diseases are rare, the clinical burden is disproportionately high relative to population incidence and prevalence. Age, sex and race also impact clinical outcomes, and patient morbidity and mortality are reflected by high need for gastroenterology, hepatology and organ transplant services.
GI highlights from the literature (8 September, 2021) FREE
Philip J Smith
doi : 10.1136/gutjnl-2021-325934
Gut 2021;70:2004-2005.
Letter: Walled of necrosis, disconnected pancreatic duct and metal stents: the debate continues!
Surinder Singh Rana, Rajesh Gupta
doi : 10.1136/gutjnl-2020-323190
Gut 2021;70:2007.
Letter: Zonulin measurement conundrum: add confusion to confusion does not lead to clarity
Alessio Fasano
doi : 10.1136/gutjnl-2020-323367
Gut 2021;70:2007-2008.
Letter: Is HBV RNA a valid marker for predicting sustained viral response for nucleoside analogue cessation?
Babu Lal Meena, Madhumita Premkumar, Akash Roy, Virendra Singh
doi : 10.1136/gutjnl-2020-323360
Gut 2021;70:2008-2009.
Letter: To WE, or not to WE, that is the question
Felix W Leung, Joseph W Leung
doi : 10.1136/gutjnl-2020-323397
Gut 2021;70:2009-2010.
Letter: Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson’s disease
Pascal Derkinderen, Wendy Noble, Michel Neunlist, Malvyne Rolli-Derkinderen
doi : 10.1136/gutjnl-2020-323482
Gut 2021;70:2010-2012.
Letter: Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Jiandong Zhou, Xiansong Wang, Sharen Lee, William Ka Kei Wu, Bernard Man Yung Cheung, Qingpeng Zhang, Gary Tse
doi : 10.1136/gutjnl-2020-323668
Gut 2021;70:2012-2013.
Letter: Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort
Seung Won Lee, Jee Myung Yang, In Kyung Yoo, Sung Yong Moon, Eun Kyo Ha, Abdullah Özgür Yeniova, Joo Young Cho, Min Seo Kim, Jae Il Shin, Dong Keon Yon
doi : 10.1136/gutjnl-2020-323672
Gut 2021;70:2013-2015.
Letter: Serotonin is elevated in COVID-19-associated diarrhoea
Seeun Ha, Byungchang Jin, Brooke Clemmensen, Paul Park, Sumaiya Mahboob, Vadim Gladwill, Farah Madhani Lovely, Andres Gottfried-Blackmore, Aida Habtezion, Subhash Verma, Seungil Ro
doi : 10.1136/gutjnl-2020-323542
Gut 2021;70:2015-2017.
Letter: Aerosol generation and droplet spread during nasogastric intubation in the COVID-19 era
Wout Verbeure, Annelies Geeraerts, I-Hsuan Huang, Lien Timmermans, Joran Toth, Hannelore Geysen, Louise Cools, Florencia Carbone, Jolien Schol, Herman Devriese, Rico Haesaerts, Hideki Mori, Tim Vanuytsel, Jan Tack
doi : 10.1136/gutjnl-2020-323836
Gut 2021;70:2017-2019.
Letter: COVID-19 and endoscopic services: the impact of delays in therapeutic colonoscopies on patients
Syazeddy Samani, Nasir Mir, David N Naumann, Michael Ding, Sharad Karandikar, Jason Goh, Marietta Iacucci, Marcus Mottershead, Vanja Giljaca
doi : 10.1136/gutjnl-2021-324112
Gut 2021;70:2019-2020.
Letter: Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
Mohamed Attauabi, Jakob Seidelin, Johan Burisch
doi : 10.1136/gutjnl-2021-324397
Gut 2021;70:2020-2022.
Diet-refractory NASH in an elderly woman
Paul Manka, Hideo A Baba, Heiner Wedemeyer, Alisan Kahraman
doi : 10.1136/gutjnl-2020-320740
Gut 2021;70:1924-1945.
Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2
doi : 10.1136/gutjnl-2011-239145corr1
Gut 2021;70:e7.
